Experienced in Hyperthyroidism

Knut T. Mai

Hessische Str. 3-4, 
Berlin, BE, DE 
Experienced in Hyperthyroidism
Hessische Str. 3-4, 
Berlin, BE, DE 
OverviewLocationsClinical Research

Overview

Knut Mai practices in Berlin, Germany. Mr. Mai is rated as an Experienced expert by MediFind in the treatment of Hyperthyroidism. His top areas of expertise are Obesity, Brachydactyly, Adrenocortical Carcinoma, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, and Hormone Replacement Therapy (HRT).

His clinical research consists of co-authoring 118 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Hyperthyroidism.

Gender
Male

Locations

Hessische Str. 3-4, Berlin, BE 10115, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Other
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
The Pathogenic Role of 11ß-hydroxysteroid Dehydrogenase in the Metabolic Syndrome - the Effect of Rosiglitazone
The Pathogenic Role of 11ß-hydroxysteroid Dehydrogenase in the Metabolic Syndrome - the Effect of Rosiglitazone
Enrollment Status: Completed
Publish Date: January 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
Effects of Negative Energy Balance on Muscle Mass Regulation
Effects of Negative Energy Balance on Muscle Mass Regulation
Enrollment Status: Completed
Publish Date: December 20, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
View 3 Less Clinical Trials

118 Total Publications

Intended isocaloric time-restricted eating shifts circadian clocks but does not improve cardiometabolic health in women with overweight.
Intended isocaloric time-restricted eating shifts circadian clocks but does not improve cardiometabolic health in women with overweight.
Journal: Science translational medicine
Published: October 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mai's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 28 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile